SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCVS Group Regulatory News (CVSG)

Share Price Information for CVS Group (CVSG)

Share Price is delayed by 15 minutes
Get Live Data
1,231.00    7.00 (0.57%)
Bid:
1,229.00
Ask:
1,230.00
Spread: 1.00 (0.081%)
Market Cap: £858.56m
CVSG Live PriceLast checked at - London Stock Exchange

Intraday CVS Group Share Chart

Capital Markets Day

8 Nov 2022 07:00

RNS Number : 5983F
CVS Group plc
08 November 2022
 

08 November 2022

CVS Group plc

("CVS" or the "Group")

 

Capital Markets Day

 

Outlining key elements behind the Group's ambition to double EBITDA over the next five years

 

 

CVS, the AIM-quoted veterinary group and one of the UK's leading providers of integrated veterinary services, today is holding its Capital Markets Day in Rotherham. The event will set out the Group's medium term plans in support of its ambition to double EBITDA over the next 5 years.  

 

The event will cover management's highly-disciplined approach to investment and acquisitions that focuses on shareholder returns, and will highlight the following key elements of its five year ambition:

 

· Organic revenue growth of between 4% and 8% per annum;

 

· Adjusted EBITDA margin between 19% and 23% subject to mix, with the opportunity to improve practice margins through investment in facilities and equipment;

 

· Continued investment in further practice refurbishment and relocations delivering high-quality clinical care, with an opportunity to invest between £30m and £50m per annum to drive additional organic growth;

 

· Greenfield investment with plans to open three greenfield sites in the financial year to 30 June 2023 with further opportunities over the five year period;

 

· On-going opportunity to invest in technology, with the Group recently announcing a new cloud based practice management system;

 

· Continued investment in people;

 

· Acquisition opportunities in the UK and scalable international consolidation opportunities which will remain subject to our disciplined acquisition criteria with expected investment of upwards of c.£50m p.a. across the five year period;

 

· Organic operating cash conversion of > 70% with leverage (net debt / bank test EBITDA) remaining less than c.2.0x; and

 

· Sustainability and ESG remain at the heart of delivering this growth strategy.

 

There will be no new disclosures on current trading conditions, with the Group's overall performance in line with market expectations.

 

Richard Fairman, CEO, commented:

"I am delighted that the strategy set out in 2019 to focus on our organic growth augmented by acquisitions has delivered strong and robust growth for the Group. Whilst we are mindful of the macro-economic backdrop, our market is resilient and the Group remains well positioned to deliver further growth.

 

Today we set out key elements behind our ambition to double EBITDA over the next five years, by delivering our purpose of providing the best possible care to animals, and our vision to be the veterinary company people most want to work for. We will outline our plans for investment across a number of areas in support of organic and inorganic growth and margin enhancement. 

 

Combining the scope for enhanced earnings with the highly cash generative nature of our business, we believe that the Group is well placed to continue to offer attractive returns to shareholders."

 

 

The presentation and Q&A will be streamed live from 12.00pm GMT, please register via the following link https://stream.brrmedia.co.uk/broadcast/6357981498f6352ab0eba0c3

 

A copy of the presentation and a webcast recording will be available on the CVS Investor Relations website following the event.

 

 

CVS Group plc via Camarco

Richard Fairman, CEO

Ben Jacklin, COO

Robin Alfonso, CFO

 

Peel Hunt LLP (Nominated Adviser & Broker) +44 (0)20 7418 8900

Adrian Trimmings / Michael Burke / Andrew Clark / Lalit Bose

 

Berenberg (Joint Broker) +44 (0)20 3207 7800

Toby Flaux / Ben Wright / Ciaran Walsh / Milo Bonser

 

Camarco (Financial PR)

Geoffrey Pelham-Lane +44 (0)7733 124 226

Ginny Pulbrook +44 (0)7961 315 138

Toby Strong +44 (0)7789 151 644 

 

 

About CVS Group plc (www.cvsukltd.co.uk)

CVS Group is an AIM-quoted fully-integrated provider of veterinary services in the UK, with practices in the Netherlands and the Republic of Ireland. CVS is focused on providing high quality clinical services to its customers and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

 

The Group has c.500 veterinary practices across its three markets, including eight specialist referral hospitals and 37 dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties), Crematoria (providing pet cremation and clinical waste disposal for CVS and third-party practices) and the Group's online retail business ("Animed Direct").

 

The Group employs c.8,100 personnel, including c.2,100 veterinary surgeons and c.3,000 nurses.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBKOBPCBDDFDK
Date   Source Headline
12th Jun 202611:08 amRNSHolding(s) in Company
12th Jun 202610:06 amRNSHolding(s) in Company
8th Jun 20262:43 pmRNSStandard form for notification of major holdings
8th Jun 20262:41 pmRNSUpdated: Transaction in Own Shares
8th Jun 20267:00 amRNSTransaction in Own Shares
1st Jun 20267:00 amRNSTransaction in Own Shares
29th May 20267:00 amRNSTotal Voting Rights
28th May 20267:00 amRNSPDMR Dealing
26th May 20267:02 amRNSChanges to NEDs' Responsibilities
26th May 20267:01 amRNSCommencement of Share Buyback Programme
26th May 20267:00 amRNSRefinancing, Launch of SBB and Acquisition
8th May 20263:55 pmRNSStandard form for notification of major holdings
30th Apr 20267:00 amRNSTotal Voting Rights
21st Apr 202612:46 pmRNSNon-Executive Director Appointment
20th Apr 20264:45 pmRNSStandard form for notification of major holdings
31st Mar 20267:00 amRNSTotal Voting Rights
30th Mar 20267:00 amRNSCEO retirement
25th Mar 20267:00 amRNSNon-Executive Director Changes
24th Mar 20267:13 amRNSResponse to CMA Summary Final Decision Report
27th Feb 20267:00 amRNSTotal Voting Rights
26th Feb 20267:00 amRNSInterim Results
30th Jan 20267:00 amRNSTotal Voting Rights
29th Jan 20262:02 pmRNSStandard form for notification of major holdings
29th Jan 20268:00 amRNSReadmission - CVS Group Plc
29th Jan 20267:00 amRNSAdmission to Trading on the Main Market of the LSE
28th Jan 20267:08 amRNSResponse to DEFRA consultation
27th Jan 20262:31 pmRNSStandard form for notification of major holdings
23rd Jan 202612:19 pmRNSPublication of Prospectus and Trading Update
23rd Jan 20267:00 amRNSProgramme completion and transaction in own shares
22nd Jan 20267:00 amRNSTransaction in Own Shares
21st Jan 20267:00 amRNSTransaction in Own Shares
20th Jan 20267:00 amRNSTransaction in Own Shares
19th Jan 20269:51 amRNSStandard form for notification of major holdings
19th Jan 20267:00 amRNSTransaction in Own Shares
16th Jan 20267:00 amRNSTransaction in Own Shares
15th Jan 20267:00 amRNSTransaction in Own Shares
14th Jan 20264:24 pmRNSStandard form for notification of major holdings
14th Jan 20267:00 amRNSTransaction in Own Shares
13th Jan 20267:00 amRNSTransaction in Own Shares
12th Jan 20267:00 amRNSBlock Listing Interim Review
12th Jan 20267:00 amRNSTransaction in Own Shares
9th Jan 20267:00 amRNSTransaction in Own Shares
8th Jan 20264:31 pmRNSStandard form for notification of major holdings
8th Jan 20267:00 amRNSTransaction in Own Shares
7th Jan 20267:00 amRNSTransaction in Own Shares
6th Jan 20269:34 amRNSDirector/PDMR Shareholding
6th Jan 20267:00 amRNSTransaction in Own Shares
5th Jan 20267:00 amRNSTransaction in Own Shares
2nd Jan 20267:00 amRNSTransaction in Own Shares
2nd Jan 20267:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.